GlassScriptPhysician profile
Peter N Jajou
NPI 1609296144
$6,261.67
in general payments reported to CMS, 2019-2025
22 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $601 · 2021: $671 · 2022: $1,624 · 2023: $491 · 2024: $820 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335 · Education: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.64 |
| Education | $422.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,804.25 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,340.32 | 2019-2025 | |
| Genzyme Corporation | $566.92 | 2019-2025 | |
| Amgen INC. | $487.69 | 2020-2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $435.56 | 2022-2025 | Sotyktu |
| Ucb, INC. | $299.18 | 2021-2025 | Bimzelx, Briviact |
| Lilly USA, LLC | $217.83 | 2019-2024 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $181.80 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $136.86 | 2020-2025 | Dupixent |
| Leo Pharma INC. | $120.94 | 2022-2025 | Adbry, Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.48 | 2024-2025 | Spevigo, Cyltezo |
| Organon LLC | $90.30 | 2025 | Hadlima |
| Galderma Laboratories, L.P. | $81.22 | 2024-2025 | Nemluvio, Aklief |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Arcutis Biotherapeutics, INC. | $75.16 | 2024-2025 | Zoryve |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $74.95 | 2025 | |
| Botanix Sb INC | $42.29 | 2025 | Sofdra |
| Janssen Scientific Affairs, LLC | $37.24 | 2022 | |
| Lnhc, INC | $35.49 | 2025 | Zelsuvmi |
| Sun Pharmaceutical Industries INC. | $18.83 | 2025 | |
| Cipher Pharmaceuticals US LLC | $18.20 | 2025 | Natroba, Spinosad |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Jajou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.